Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study [PDF]
Dermatology and Therapy, 2023 Introduction We evaluated the anti-interleukin-36 receptor antibody spesolimab in patients with moderate-to-severe palmoplantar pustulosis (PPP). Methods This phase IIb trial comprised a loading dose period to week (W) 4, then maintenance dosing to W52 ...
Alexander Navarini, David Burden
exaly +3 more sources
Dermatology and TherapyIntroduction Spesolimab, a selective, humanised monoclonal antibody targeting the interleukin-36 receptor, is approved for the treatment of generalised pustular psoriasis (GPP).
Diamant Thaci, Milan Anadkat
exaly +4 more sources
Management of Generalized Pustular Psoriasis Flare with Intravenous Spesolimab Followed by Long-Term Treatment with Subcutaneous Spesolimab: A Case Report [PDF]
Case Reports in DermatologyIntroduction: This case report describes the clinical course and treatment of generalized pustular psoriasis (GPP) flare with intravenous (i.v.) spesolimab, an anti-IL-36R antibody, and subsequent long-term disease management with subcutaneous
Angad Arinder Chadha
doaj +3 more sources
Spesolimab for treatment of generalized pustular psoriasis of pregnancy [PDF]
PregnancyIntroduction Generalized pustular psoriasis (GPP) is a severe, desquamating skin disorder associated with pregnancy that presents as fever, fatigue, malaise and sterile pustules.
Jason Bunn +9 more
doaj +3 more sources
Combination therapy with spesolimab and apremilast for refractory generalized pustular psoriasis: a case report [PDF]
Frontiers in MedicineGeneralized pustular psoriasis (GPP) is a rare, life-threatening neutrophilic dermatosis characterized by recurrent episodes of widespread sterile pustules, systemic inflammation, and potential multi-organ failure.
Yuwei Li +4 more
doaj +4 more sources
Spesolimab Treatment in GPP: Impact of IL-36RN Mutations and Concomitant Plaque Psoriasis [PDF]
Clinical, Cosmetic and Investigational DermatologyWei Li,1– 3,* Jingyao Liang,2,* Yuwu Luo,2 Shuting Chen,2 Manqi Xia,2 Hui Ye,2 Bin Yang,1,3 Quan Luo2 1Department of Dermatology, First Affiliated Hospital of Jinan University, Guangzhou, 510630, People’s Republic of China; 2Department of
Hui Ye, Manqi Xia
exaly +4 more sources
Successful treatment of recalcitrant generalized pustular psoriasis of pregnancy with spesolimab
Journal of Dermatological TreatmentGeneralized pustular psoriasis (GPP) in pregnancy can lead to severe complications for both mother and fetus. The treatment of this disease is challenging, especially in recalcitrant and severe cases. Until present, there are no evidence-based guidelines
Ruoyu Li, Ping Tu
exaly +5 more sources
Effectiveness and Safety of Spesolimab in Adolescents and Adults with Generalized Pustular Psoriasis [PDF]
Pragmatic and Observational ResearchChun-Ting Li,1 Jin-Zhu Guo,1 Yu-Ting Zhou,1 Jing Su,2 Wen-Hui Wang11Dermatology Department, Peking University Third Hospital, Beijing, 100191, People’s Republic of China; 2School of Basic Medical Sciences, Peking University Third Hospital, Beijing ...
Li CT, Guo JZ, Zhou YT, Su J, Wang WH
doaj +2 more sources
Dermatology and Therapy, 2023 Introduction Generalized pustular psoriasis (GPP) is a rare and potentially life-threatening skin disease. The global Effisayil 1 study investigated the efficacy and safety of spesolimab, a humanized monoclonal antibody targeting the IL-36 receptor, in ...
Zhiqi Song, Quanzhong Liu
exaly +2 more sources
IL-36 Receptor Antagonist Spesolimab for Generalized Pustular Psoriasis Combined with Palmoplantar Pustulosis: A Case Report [PDF]
Clinical, Cosmetic and Investigational DermatologyHongyan Tan,1,* Yu Zhang,2,* Bin Zhang,3 Juan Wang,3 Zhong Zhang,3 Jizhen Zhong,3 Xiao Qiu,3 Xiangyu Hu,3 Ling Tang4 1Department of Dermatology, Shantou Hospital of Traditional Chinese Medicine, Shantou, 515031, People’s Republic of China;
Tan H +8 more
doaj +2 more sources